Laura Testa

[Laura Testa @LauraTestaMD]

I am happy that reviewer n3 cannot imagine a reality where people need CVCs and there is no ultrasound. Life can be better with more resources.

Congratulations to the authors and all our fellow colleagues who battle to deliver the best possible care wherever it is needed.

[Marcio Boniatti @MarcioBoniatti]

Today we received responses from reviewers about an article that investigated a training program for CVC insertion.Reviewers, please be empathetic in the responses. Don't be disrespectful like the reviewer 3. Total ignorance of low-middle income country conditions @dvarvaki

[Medscape PT @MedscapePT]

ASCO 2020: Resultados dos principais estudos sobre câncer de mama e tumores ginecológicos comentados pelas Dras. Laura Testa e Maria del Pilar Estevez-Diz. https://t.co/AnQhQa3PN3

[Laura Testa @LauraTestaMD]

Amazing news from MONARCH E trial.
Grateful to all participating!

[Laura Testa @LauraTestaMD]

@AdrianaHepner @amenzies9 @MPostow @HTawbi_MD @jasonlukemd @KimrynRathmell @DrChoueiri @montypal @m_e_nielsen @FaltasLab @ERPlimackMD @BernardAFox @alexshoushtari @RiyueSunnyBao @Aiims1742 @JaniceM10 @jan_beumer @mcquadeMDLAc @evanlipson @YoninaMG @DrBetofMDPhD @OmidHamidMD @FunchainMD @MattCarlino @inespiresilva @DrBenKong @Mal_Itchins @mauriciofribei1 @renata_bonadio @pires_veridiana @davidmuniz_ I pledge to oppose racism and hate through active allyship, continuous unlearning, learning, and listening. Join me by nominating 5 others to do the same. @BraghiroliIgnez @pilarestevezmd @RGuindalini @DrRBarroso @f_g_zampieri @MarianaBrandao0

[Laura Testa @LauraTestaMD]

@DavidFajgenbaum @ASCO Thank you so much for your inspiring talk! Hope, action, laughter, connection and communication! Stay safe!

[Paulo Hoff @paulohoff10]

Today we discharged home a 97 year old woman who had been admitted to our hospital with a severe COVID infection. Best Easter present ever!

[Lauro Jardim @laurojardim]

Mais 100 UTIs para o coronavírus no Rio | Lauro Jardim - O Globo https://t.co/PNrKZxaXhq

[FMUSP - Oficial @FMUSPoficial]

#fmusp #fmuspoficial #medicinausp #kidssavelives

[Medscape PT @MedscapePT]

Inibidores da PARP dominaram as novidades em tumores ginecológicos da #ESMO19, assista ao vídeo com um resumo do que foi apresentado: https://t.co/BPW2t8zqI0

[Laura Testa @LauraTestaMD]

Great to be around my Cardio Onc friends talking about exercise! Impressive meeting, congratulations to all the organizers!

[Carolina Silva, MD, PhD @carolinasilvaMD]

Excellent talk at #GCOS2019 by my dear friend @LauraTestaMD on the role of exercise on cancer patients. Congrats 👏👏👏👏👏👏👏👏👏

[Veridiana Pires De Camargo @pires_veridiana]

Our 10 year follow up of 100 adult osteossarcomas treated with cis -dox without MTX. 5Y OS 67.3%

[Medscape PT @MedscapePT]

A @LauraTestaMD acaba de gravar com o @GilbertoAmorim6 sobre o melhor em câncer de mama na #ESMO19. Acompanhe a nossa cobertura no #MedscapePT

[Gilberto de Castro Junior @GilbertodeCas13]

ICESP team at ESMO2019: many presentations and authorships! Very proud to be part of it! #icesp #ESMO2019

[Laura Testa @LauraTestaMD]

@CarolCardioOnc Welcome back ❤

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

Our Accomplice Guide — For the Breast of Us #bcsm https://t.co/Po50OJQ8tM

[Laura Testa @LauraTestaMD]

@itsnot_pink I usually already know trials open in my institution. And I look for trials in and outside my workplace every time we start a new treatment, even if there is a good standard of care option.

[FabriceAndre @FAndreMD]

we are looking for 2 highly motivated MDPhD to develop clin research and AI-based molecular predictors in the precision medicine center @GustaveRoussy @centralesupelec . excellent mentors. grant for 5 years. pls send applications to [email protected]

[Laura Testa @LauraTestaMD]

@f_g_zampieri Very interesting point really, although I want my boss to stick around for at least 20 more...

[Laura Testa @LauraTestaMD]

@itsnot_pink
There you go

[Laura Testa @LauraTestaMD]

@itsnot_pink Julia, patients with other germline mutations such as RAD51c might be responders to PARP inhibition. Unfortunately there is no hint yet that somatic mutations will be good biomarkers for PARPi response.
Excluding HER2+ patients is actually a matter of simplifying study design...